Excellus BCBS

Does Excellus BCBS cover Mounjaro?

Quick answer · Type 2 Diabetes

Excellus BCBS covers Mounjaro for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered (preferred drug). No additional clinical requirements listed.
  • ACA Marketplace: Covered (preferred drug). No additional clinical requirements listed.

Last verified June 5, 2026. Policy effective January 1, 2024. Source: diabetic-incretin-mimetic-agents-policy-pdf. How we verify this data →

Check your card for your exact plan →

Mounjaro for Type 2 Diabetes

What Excellus BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

No additional clinical requirements are listed beyond the diagnosis.

Qualification pathways

You can qualify through any one of these.

Initial approval for Type 2 Diabetes

All of:

  • Diagnosis of Type 2 Diabetes Mellitus

Documentation to bring

  • Documentation of Type 2 Diabetes Mellitus diagnosis
  • Progress notes documenting previous treatments and treatment history
  • Laboratory test results as applicable
  • Documentation supporting medical necessity of requested product

Quantity limits

  • 2.5mg — 4 pens (2 mL); 12 pens (6 mL) — limited to 4 pens per 365 days of 2.5 mg dose to allow for titration to maintenance dosing (84-day)
  • 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 4 pens (2 mL); 12 pens (6 mL) (84-day)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Clinical documentation must be submitted at recertification supporting continued medical necessity; ongoing use must reflect current formulary. Recertification may require trial of more cost-effective alternatives (generics, biosimilars, or other guideline-supported options) as they become available.

Policy note: Mounjaro Pen is listed as a preferred agent requiring only a T2DM diagnosis. Special quantity limit for 2.5 mg dose: 4 pens (2 mL) per 365 days to allow for titration to maintenance dosing; all other doses: 4 pens (2 mL) per 28 days. Collective GLP-1/GIP agonist quantity limits apply cumulatively across all products regardless of indication: maximum 14 fills of 28/30-day supply per rolling 365 days OR maximum 5 fills of 84/90-day supply per rolling 365 days. Only one GLP-1/GIP product at one strength may be approved per 28/30-day period. Weight loss and cardiovascular indications are handled under a separate policy (PHARMACY-03). New York State insurance law stepwise-therapy override provisions apply.

Policy effective January 1, 2024 · verified June 5, 2026 · source: diabetic-incretin-mimetic-agents-policy-pdf

ACA Marketplace

Covered (preferred drug)

No additional clinical requirements are listed beyond the diagnosis.

Qualification pathways

You can qualify through any one of these.

Initial approval for Type 2 Diabetes

All of:

  • Diagnosis of Type 2 Diabetes Mellitus

Documentation to bring

  • Documentation of Type 2 Diabetes Mellitus diagnosis
  • Progress notes documenting previous treatments and treatment history
  • Laboratory test results as applicable
  • Documentation supporting medical necessity of requested product

Quantity limits

  • 2.5mg — 4 pens (2 mL); 12 pens (6 mL) — limited to 4 pens per 365 days of 2.5 mg dose to allow for titration to maintenance dosing (84-day)
  • 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 4 pens (2 mL); 12 pens (6 mL) (84-day)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Clinical documentation must be submitted at recertification supporting continued medical necessity; ongoing use must reflect current formulary. Recertification may require trial of more cost-effective alternatives (generics, biosimilars, or other guideline-supported options) as they become available.

Policy note: Mounjaro Pen is listed as a preferred agent requiring only a T2DM diagnosis. Special quantity limit for 2.5 mg dose: 4 pens (2 mL) per 365 days to allow for titration to maintenance dosing; all other doses: 4 pens (2 mL) per 28 days. Collective GLP-1/GIP agonist quantity limits apply cumulatively across all products regardless of indication: maximum 14 fills of 28/30-day supply per rolling 365 days OR maximum 5 fills of 84/90-day supply per rolling 365 days. Only one GLP-1/GIP product at one strength may be approved per 28/30-day period. Weight loss and cardiovascular indications are handled under a separate policy (PHARMACY-03). New York State insurance law stepwise-therapy override provisions apply.

Policy effective January 1, 2024 · verified June 5, 2026 · source: diabetic-incretin-mimetic-agents-policy-pdf

Why Mounjaro requests get denied by Excellus BCBS

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Mounjaro and Zepbound are the same molecule with different approved uses; a request for Mounjaro under a diagnosis that matches Zepbound is routinely denied.

Frequently asked questions

Does Excellus BCBS cover Mounjaro?
Excellus BCBS covers Mounjaro for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
How long does a Mounjaro approval last with Excellus BCBS?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does Excellus BCBS require to renew Mounjaro?
Clinical documentation must be submitted at recertification supporting continued medical necessity; ongoing use must reflect current formulary. Recertification may require trial of more cost-effective alternatives (generics, biosimilars, or other guideline-supported options) as they become available.
How current is this information?
This page reflects Excellus BCBS's written policy as of January 1, 2024, last verified against the source document on June 5, 2026.

Other medications under Excellus BCBS

Mounjaro coverage under other plans

All insurance plans · All medications

This page summarizes Excellus BCBS's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.